Wegovy (Semaglutide Injection) Wegovy is the semaglutide solution for weight management, offering once-a-week injections
They start as macules and target-like lesions with erythema and dark necrotic centers and develop into vesicles, erosions, or ulcerations with epidermal detachment
Beyond weight, the SELECT trial (N=17,604) published in the New England Journal of Medicine in 2023 showed that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% compared to placebo in adults with overweight or obesity and established cardiovascular disease, over a median follow-up of 39.8 months (HR 0.80 to 95% CI 0.72 to 0.90)
Their findings match existing clinical data, supporting the notion that probiotics can influence the MGBA, perhaps as a complementary method of intervention against the advancing PD phenotypes
It is essential that any decision to use these medications together is made by a qualified healthcare professional who can monitor for adverse effects and adjust treatment as necessary
Ingredients Trpti OEA, CQR-300 Cissus Extract, Chromium (as Chromium Picolinate), Vegan Capsule (Hypromellose), Microcrystalline Cellulose, Magnesium Stearate, Silica